Pharmacy and Drug Development

Abstract

Dengue virus is a human pathogen that infects roughly 390 million people each year, with a quarter of them developing clinical symptoms. Although progress has been made in understanding the biology of dengue fever, there is still no licensed vaccine or antiviral medication available. There is yet no effective antidote for this virus. Patients' treatment is limited to symptomatic relief and Care that is supportive. As a result, the discovery of dengue treatments is critical. The focus of this review is on the few compounds that have been tested in dengue virus patients: Balapiravir, chloroquine, lovastatin, prednisolone, and celgosivir are some of the drugs used to treat HIV. Balapiravir was expected that the medication would also be effective against DENV because the RdRp of DENV and HCV are comparable. The lessons that these have taught us Clinical trials can be extremely useful in the development of future trials for the dengue virus's next-generation inhibitors.

Introduction

Infection with the dengue virus (DENV) is the most dangerous mosquito-borne disease in the world, impacting 2.5 billion people in tropical and subtropical areas [1], [2]. DENV, a member of the Flaviviridae family, is passed from infected female Aedes mosquitoes, particularly Aedes aegypti or Aedes albopictus, to humans [3,4]. The characteristics of the four dengue virus serotypes (DENV 1-4) are similar [5, 6]. DENV can result in primary infection or secondary infection, two different forms of illnesses. Dengue fever is an acute febrile sickness brought on by an initial infection. Hemorrhagic fever (DHF) or dengue shock syndrome (DSS) are the outcomes of reinfection, which is more severe [7]. Both DHF and DSS have a high mortality rate and can result in patient death [8]. Therefore, dengue is considered a fever that poses a serious risk of death. Additionally, there is a need to create a vaccine that is effective, affordable, and secure that can combat all four DENV serotypes. Dengue envelop protein mediates the attachment of DENV to certain receptors, which starts the life cycle of the virus. During receptor-mediated endocytosis, the viral particle is merged into acidic lysosomes after engagement. The viral particle then detaches from its coating and the RNA is released into the host cell, where it controls the production of viral proteins. Tens of thousands of copies of the viral molecules are created from a single viral molecule in just a few hours following infection, causing cell damage and, in serious forms, death [9]. Three of these proteins are structural—the core protein, a surface protein, and an exterior protein—and seven of them are simplified and made. The sequence of the genes is as follows: 5′-CprM (M)-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3′ (Figure 1) [10]. Retinoic acid inducible Gene-I, melanoma differentiation related gene-5, and Toll-like receptor-3 are all implicated in the beginning of an efficient IFN production against DENV. This is due to the enhanced transcription of both extracellular and intracellular pattern recognition receptors [11]. There isn't a vaccine preventing dengue infection at the moment. It has been difficult to produce a dengue vaccine since DENV has four different serotypes. There is a critical must to create affordable, less harmful anti- dengue medicines that can combat all dengue serotypes. 75 years ago, heterochromatin was first identified. Silence genes were discovered to be present shortly after. Using RNA interference, this heterochromatin generates short RNAs that control the alteration of proteins and DNA in heterochromatic repeats and transposable elements [12]. A quick and easy way to silence gene expression in a variety of organisms is through double-stranded RNA-mediated interference (RNAi) [13]. In addition to serving as a line of defense from entering viruses, RNAi and other silencing mechanisms are crucial in controlling how cellular genes are expressed. Researchers demonstrated that RNAi is an effective strategy for treating flavivirus infections in the host and preventing flavivirus propagation via vector [14], [15].

Figure 1: Structure of Dengue virus [16]

Dengue Transmitted to Humans

A cycle of communication from human to mosquito to human allows the dengue virus to multiply (Figure 2). [17] The typical time frame for developing viremia, or a state when there is a high concentration of the dengue virus in the blood, is four days after being bitten by an infectious Aedes aegypti mosquito. Viremia typically lasts five days, although it can last up to twelve days. [18] The person often has no signs of dengue on the first day of viremia. The individual experiences dengue fever characteristics five days after being bitten by an infected mosquito. These illnesses can last a week or more. A mosquito turns into a dengue vector once it has consumed the blood of a person who is afflicted with the virus. [19] The moment of viremia, when the infected person's blood contains high concentrations of the dengue virus, is when the mosquito must feed on blood. The virus is spreading throughout the mosquito's body for eight to twelve days after it has been ingested in the blood meal. The infection develops can continue to spread the dengue virus to another person while feeding after this time. [20] Does a dengue-infected mosquito simply spread the illness to the next person it bites? No, a mosquito that contracts dengue will carry the virus for the rest of its life. Healthy people can contract the dengue virus from infected mosquitoes for the remainder of their lives, which is typically a three- to four- week timeframe. [21] As their primary data of fuel, plant nectars, fruit juices, and other plant sugars are consumed by both male and female mosquitoes. So why do mosquitoes bite people? Female mosquitoes bite humans because they need blood to lay their eggs. Aedes aegypti frequently consume many blood meals prior to depositing a lot of eggs, and each female mosquito has the capacity to lay multiple batches of eggs throughout her lifespan. [22] The dengue virus can be found in the salivary glands of infected female mosquitoes. How can the virus enter a human being from the salivary glands of a mosquito? An infected female mosquito injects its saliva into the human host during a blood meal to stop the performer's blood's ability to clot and to facilitate eating. [23] The dengue virus infects the host through this infusion of saliva. Is the dengue virus only spread to people through mosquito bites? Rarely, dengue can be spread by blood transfusions from contaminated donors or organ transplants. [24] There is proof that a pregnant woman who has the dengue virus can pass it on to her fetus. Although these infrequent occurrences, mosquito bites are the primary method of transmission for dengue diseases [25].

Figure 2: dengue virus cycle in humans and mosquito [26]

Dengue Mosquito Life Cycle

Mosquito life cycles are intricate (Figure 3). Mosquitoes modify their appearance and environments as they grow. In water-filled enclosures, female mosquitoes typically lay their eggs just above surface. Tires, buckets, birdbaths, water storage jars, and flower pots are a few examples of these vessels. [27] The mosquito eggs hatch into larvae when the containers fill with water, frequently following a downpour. The larvae are aquatic, which means that they are reliant on aquatic microbes for their food. Larvae get through the three stages of development during which they molt, or shed, their skin. The first through fourth instars refer to these pupal stages. [28] A larva passes through metamorphosis into a new form known as a pupa, the "cocoon" development for the mosquito, when it is a fully developed fourth instar. The mosquito is also waterborne at this stage of its life cycle. The fully formed adult mosquito matures and emerges from the pupa's skin after two days. The adult mosquito no longer lives in water and can fly. [29] Its environment is on land. What occurs if it doesn't rain? The Aedes aegypti mosquito has evolved so that its eggs can endure dry circumstances for a long period of time. [30] When mosquito eggs are put in a dry container, they don't hatch until the compartment is filled with water. [31] It is now very challenging to entirely eradicate mosquito populations due to this adaptability. Although infestations are more prone to occur where there are many humans in close contact with many mosquito vectors than in more remote locations, dengue can be more dangerous in densely populated regions. [32] Dengue infections are a significant public health issue in equatorial nations like Indonesia, India, Brazil, Thailand, Sri Lanka, and Myanmar that endure tropical monsoon periods. [33]

Figure: 3 Aedes aegypti life cycle [34]

Epidemiology of DENV

DENV can lead to a number of mild to serious illnesses when a mosquito bite, mainly Aedes aegypti or Aedes albopictus, is the source. [35] The United States' program to eliminate the mosquito, which came to an end in 1970, waned over time in other nations, and the mosquito started to re-infest areas where it had been previously eradicated. The geographic spread of Aedes Aegyptus was significantly greater in 2002 than it had been prior to the control and elimination, [36] which led to an increase in dengue infections. There are four distinct serotypes of DENV. Lifelong resistance to a particular DENV genotype is provided by a single initial infection. Conversely, the chance of developing a severe case of dengue increases when a person is infected with a different DENV antigen. [37] 

Pathogenesis of Dengue virus

A complicated relationship seen between human immune system and viral virulence factors complicates the pathogenesis of DHF/DSS, the most severe kind of DENV infection. [38] Randomized controlled research have shown an immune system connection since there is an increased risk of DHF with secondary DENV infection and in children born to DENV- immune mothers within the first year of life. [39] These results gave rise to the concept of specific antibodies immune enhancement (ADE) of infection. The peak viremia was higher in patients with severe secondary DENV infection, validating the ADE etiology theory. In vitro antibody amplification of DENV infection in monocytes was linked to an increased risk of DHF. [40] There is a correlation between serious illnesses and elevated cytokine levels, such as interferon (IFN), tumor necrosis factor (TNF), and interleukin (IL)-10. The development of serotype-reactive low-affinity DENV-specific T cells and the engagement of CD8+ T cells have been associated with the extent of the illness [41]. After an infection with a particular serotype, an individual is immune to re-infection with the same serotype. However, infection with a different serotype can occur subsequently, as the heterologous immunity is short-lived. Based on many cohort studies, the heterotypic protective immunity gradually wanes in 1 or 2 years subsequently [42].

Diagnosis Process for DENV

Dengue diagnosis requires the development of a diagnostic testing of infection. Surveillance and response and case identification are challenging owing to the fact that dengue viruses can produce asymptomatic illnesses and a range of clinical signs from a mild, nonspecific febrile sickness to a fatal hemorrhagic disease. [43] The patient's age, immunological state, genetic disorder, and the strain and serotype of the infecting virus are all significant risk factors for DHF. The virus is typically found by growing it in cell culture or by using serology to look for anti-dengue antibodies. It is possible to find and grow viral RNA and specific dengue virus antigens in vitro. [44]

Purpose of the Study

• The goals of this project are to get an inclusive considerate of the medical problem being researched.

• To learn more about the variables that contribute to the development of Dengue virus infection.

• To have a better grasp of the many diagnostic procedures used to diagnose this ailment.

• To gain a systematic understanding of the disease, as well as its cause, signs and symptoms, consequences, and medical and nursing treatment choices.

• The determination of this investigation was to understand more about Dengue virus infection in the world.

• Designate the epidemiology of Dengue virus infection.

• Review the exhibition of a patient infected with Dengue virus infection.

• To find out approved therapeutic practice for Dengue virus infection.

• Recapitulate the role of the interprofessional healthcare team in Dengue virus infection illness preclusion and control measures.

Materials and Procedures

The methods employed in this investigation are discussed in this chapter. It is a explanation of the study environment. The study population, the study sample, the research equipment, the technique, and the data analysis are all factors to consider.

Research Methodology

This is a summary of prior studies on different clinical trials as a dengue virus disease treatment.

Inclusion and Exclusion Criteria

All studies on Drug candidates in clinical trials for dengue virus disease.

Data Collection Procedure

Data was gathered directly from prior study articles, while another portion was gathered through searching the internet for relevant information. The activities of many treatments were recorded.

Method of Data Analysis

All of the information gathered from prior study publications was numerically coded and imported.

Vaccination

There are particular difficulties in creating a dengue vaccine. The four dengue serotypes are present across the world, and exposure to one of them results in life-long protection from the same serotype of infection, [46] but merely momentary defense against the additional 3 serotypes. Additionally, dengue is distinct in that subsequent illnesses with various serotypes, the chance of getting a serious and maybe fatal illness [77]. There is few knowledge of the virus's interactions with the immune system and how specific forms of innate immunity can aggravate an illness. Consequently, a reliable and efficient dengue vaccine should be tetravalent and provide substantial and long lived protection against all 4 serotypes concurrently in to reduce the possibility of vaccination recipients becoming sensitized a really bad illness [78]. Several dengue vaccine candidates are in various stages of development. Tetravalent combinations of live attenuated viruses representing each serotype are used in the more sophisticated versions. Three of the leading possibilities have been developed using various attenuation mechanisms: [47]

1. Viral interaction amongst some of the live vaccine components prevents a single inoculation from providing protection against all four serotypes.

2. Booster dosages administered no more than six months apart are useless. [48]

Live attenuated vaccines need to be administered three times over the course of a 12-month dosing period in order to produce balanced neutralizing antibody responses to all four serotypes. As a consequence, there is a chance that an insufficient response generated by the previous vaccines will worsen illness if infection arises between the first and last vaccination. [49]

Table 1: Available Dengue vaccine

Balapiravir

A powerful blocker of the hepatitis C virus's (HCV) in vitro replication, balapiravir is a prodrug of the nucleoside analogue 4′-azidocytidine (R1479) [50]. The parent substance functions as a viral RdRp antagonist once it enters the host cell and is phosphorylated to form its 5′-triphosphate metabolite (Figure 1). Patients with chronic HCV infections have shown that balapiravir is effective [51,52]. Due to an inadequate advantage to relative risk, the clinical development of this drug for the treatment of chronic HCV was stopped [53].

It was expected that the medication would also be effective against DENV because the RdRp of DENV and HCV are comparable. With EC50 values in the range from 1.9 to 11M in human hepatoma (Huh-7) cells and 1.3 to 6.0 M in derived from human macrophages and dendritic cells, [54] balapiravir was demonstrated to suppress the replication of several DENV serotypes and strains (both lab and clinical) [55]. Peripheral blood mononuclear cells (PBMCs) were used to verify the antiviral activity, and the EC50 values ranged from 0.10 to 0.25 M [56]. Based on these objective measures, a DENV treatment trial with oral medication doses of 1500 and 3000 mg BID was developed. [57] Median plasma sensitivities as a result of this were 3.56 M and 5.85 M, correspondingly, which are 1.6- fold and 2.6-fold greater than the EC50 value discovered in macrophages [58]. The lack of potency has been attributed to a number of factors. First off, the drug might not be as effective when viremia is at its highest degree. In fact, balapiravir was 52 times less efficacious in PBMCs when added after the start of an in vitro infection [59]. The operation of balapiravir it seems to be cell form as it is generally less efficient in Huh-7 and adenocarcinomic human alveolar basal epithelial (A549) cells and to a lesser extent in human monocytic THP-1 cells than in primary cells, in addition to being less active when introduced after infection [60]. This could be because various cells have varying capacities for phosphorylating balapiravir, which produces the drug's active triphosphate metabolite.[61]

Figure 4: Mechanism of action balapiravir [62]

Chloroquine

In regions where malaria is still susceptible to its actions, chloroquine is primarily used to prevent and cure malaria. [63] Complex cases, susceptibility testing, and specific forms of malaria frequently demand for extra or alternative medicine. [64] Rheumatoid arthritis, lupus erythematosus, and amebiasis that develops beyond the intestines are other conditions that may respond to chloroquine treatment. [65] It seems safe even though it hasn't been fully studied during pregnancy. [66,67] Early in the pandemic, it was examined to treat COVID-19, but these studies were mainly stopped in the summer of 2020, and it is not advised for this use. [68] It is consumed orally. Muscle issues, appetite loss, diarrhea, and skin rashes are typical adverse effects. [69] Vision issues, muscular damage, convulsions, and low blood cell levels are serious complications. The pharmacological class 4-aminoquinoline includes chloroquine. [70] It acts as an antimalarial by inhibiting the asexual stage of the malaria parasite's life cycle inside the red blood cell. [71] It's uncertain how it functions in lupus erythematosus and rheumatoid arthritis. [73] Hans Andersag made the discovery of chloroquine in 1934. [72] It is listed as one of the Essential Medicines by the Health Organization. [73] It is accessible as a generic drug.

Celgosivir

Celgosivir has shown a synergistic impact when combined with pegylated interferon alfa- 2b and ribavirin, both in vitro and in phase II clinical trials that last up to a year in patients with chronic HCV infection. [80] Celgosivir is ineffective as a single for the management of HCV. Celgosivir could prove to be a crucial part of standard treatment and could aid in preventing the development of drug resistance. Celgosivir's safety in humans has to be confirmed by long-term toxicity testing. [75] Celgosivir is typically well-tolerated and safe, but it doesn't appear to lower dengue fever patients' virus loads or fever incidence.[76]

Drugs targeting dengue proteins

There are a number of direct-acting antiviral medications (DAAs) that target particular dengue proteins. It is advisable for interested readers to read these excellent assessments on the most recent developments, chemical structures, and mechanisms of action of certain novel DAAs and therapeutic antibodies [91–93], which will not be covered in-depth here. Instead, we've provided thorough summaries of the development of various dengue- treatment strategies. [78]

Figure 5: Schematic view of dengue virus replication cycle. [79]

MTase Inhibitors

On the newly synthesized positive-strand RNA, the NS5-MTase domain catalyzes RNA cap methylation at the N7 and 2'O sites [94]. It can also methylate the internal adenosine at the 2'-OH position of the ribose in the viral RNA genome. N7 methylation of the RNA cap is necessary for efficient translations, as MTase mutations that abolish N7 methylation are fatal for flaviviral replication [94]. The development of new substances that preferentially bind to and inhibit MTase (like "compound 10") is ongoing. Fit chemicals are currently being unmovingly isolated for additional testing [95]. Nucleoside analog (NITD008) NITD008, an adenosine analog, has been found to have antiviral effects by blocking DENV RdRP and stopping RNA chain synthesis. [96]. In vitro DENV 1-4 replications were discovered to be inhibited by NITD008. DENV-infected mice treated with NITD008 had decreased viral loads, proinflammatory cytokines, and mortality. However, this medication showed significant negative effects during preclinical toxicology studies in mice; as a result, it was not further developed for human trials [96].

Helicase Inhibitors

Following RNA replication, helicase antagonists prevent DENV NS3 from unraveling [97]. Furthermore, the small-molecule helicase blocker ST-610 was found. This medication effectively and precisely suppressed all four DENV serotypes in vitro [98]. It successfully decreased viremia in mice while being well absorbed. Due to its poor oral bioavailability and requirement for parenteral administration, this drug's use is restricted, particularly in environments with limited resources.

Protease Inhibitors

A serine processor called DENV NS3 needs the cofactor NS2B to work. The production of structural and nonstructural proteins throughout proper co- and post-translational processing of the polypeptide during DENV replication is necessary for viral replication [99]. For these stages, many proteases (NS2B/NS3) synthesized by the host and virus are needed. Viral proteases are proven antiviral targets, as demonstrated by the extraordinarily powerful antagonists of HIV-1 and HCV proteases [99]. Given that the DENV 1-4 NS3 protease shares 63–74 percent of its amino acid sequence, it is possible to produce proteolytic enzymes that are efficacious against so many four DENV serotypes, however the barrier to resistance may be low. Although some potential antagonists have been identified, human clinical trials for these drugs have not yet been conducted [92].

NS4B Inhibitor

Although it has no recognized enzymatic function, the transmembrane protein NS4B is essential for the production and attachment of the active viral replication complex onto ER membranes [100]. NS4B obstructs IFN-/ signaling to promote virus replication [101]. Many investigators have identified substances that interfere with NS4B to prevent DENV replication. NITD618 was one of the substances identified and demonstrated to be effective against all four DENV serotypes [102]. However, due to its poor pharmacokinetic properties and high lipophilicity, NITD618 makes in vivo experiments challenging [92]. Lycorine, a plant alkaloid that prevented the replication of WNV, YFV, and DENV 1-2, was another NS4B antagonist [103]. Another compound, SDM25N, was discovered to be effective towards DENV 2 in vitro.

Entrance/Fusion Blockers

E protein, which includes three cysteines, plays a major role in mediating DENV penetration into the host cell. (DI, DII, and DIII) domains [84]. in the advanced E protein, which is structured into 90 DENV particles homodimers with a covert fusion loop the dimer interaction itself. the initial stage of a virus entrance is when viral E protein binds to many cellular receptor and/or connection kinds factors (such as CD14, GRP78, laminin receptor, mannose receptor, DC-SIGN, heparin sulfate, and TAM proteins) [85]. binding is done, Viral internalization is regulated by clathrin Endenosis [85] The E protein undergoes structural changes and permutations inside the cell as a result of the acidic pH environment, exposing the fusion loop and inserting it into the endosomal membrane. Next, a membrane fusion pore forms, allowing viral RNA to enter the cytoplasm. Membrane fusion antagonists have been created and recently recommended [85]. They bind to different regions of the structural framework. Future optimisation, animal, and clinical investigations are necessary before their application [82].

DNA-Based Analog (NITD008)

Adenosine analog NITD008 was created, and it has been shown to have antiviral effects by inhibiting DENV RdRP and stopping the production of RNA chains [90]. Research published in vitro revealed that NITD008 decreased DENV 1-4 replication. NITD008- treated DENV-infected mice showed decreases in viral load, proinflammatory cytokines, and mortality. This medication was not subsequently researched for human trials since it also caused substantial side effects throughout preclinical toxicology investigations in mice [90].

Table 2: Available drug

Conclusion

Over 2.5 billion people at risk of dengue illness, dengue is a challenge for global health. Dengue cases have increased dramatically over the past 50 years for causes that are still not fully understood. A severe infection can be fatal while being a short-term condition with no substantial long-term aftereffects. Dengue's pathophysiology still seems to be unknown, but it is generally agreed that the "severe disease" is caused by a reaction seen between virus and the host's over reactive immune system. There is no specific treatment for the illness; instead, palliative therapy is the only method of treatment, along with careful fluid control during the crucial stage and ongoing observation. The benefits of a dengue vaccine are enormous, yet progress in this area is delayed. There is a wide range of medicinal plant parts processing a variety of pharmacological action that were used in the treatment of several diseases [105-111].

Acknowledgments

We thank members of our groups for insightful discussions during this study.

Disclosure Statement: The authors have no conflicts of interest.

Funding
This study received no specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Declaration of generative AI and AI-assisted technologies in the writing process No AI and AI-assisted technologies used in the writing process
 

References

1. Chambers, Thomas J., Chang S. Hahn, Ricardo Galler, and Charles M. Rice. “Flavivirus genome organization, expression, and replication.” (1990): 649-688.
   View at Publisher | View at Google Scholar
2. Tassaneetrithep, Boonrat, Timothy H. Burgess, Angela Granelli- Piperno, Christine Trumpfheller, Jennifer Finke, Wellington Sun, Michael A. Eller et al. “DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells.” The Journal of experimental medicine 197, no. 7 (2003): 823-829.
   View at Publisher | View at Google Scholar
3. Heinz, Franz X., G. Auer, K. Stiasny, H. Holzmann, C. Mandl, F. Guirakhoo, and C. Kunz. The interactions of the flavivirus envelope proteins: implications for virus entry and release. Springer Vienna, 1994.
   View at Publisher | View at Google Scholar
4. Heinz, Franz X., Karin Stiasny, Gudrun Püschner-Auer, Heidemarie Holzmann, Steven L. Allison, Christian W. Mandl, and Christian Kunz. “Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM.” Virology 198, no. 1 (1994): 109-117.
   View at Publisher | View at Google Scholar
5. Mackenzie, Jason M., Malcolm K. Jones, and Edwin G. Westaway. “Markers for trans-Golgi membranes and the intermediate compartment localize to induced membranes with distinct replication functions in flavivirus-infected cells.” Journal of virology 73, no. 11 (1999): 9555-9567.
   View at Publisher | View at Google Scholar
6. Solomon, T., and M. Mallewa. “Dengue and other emerging flaviviruses.” Journal of Infection 42, no. 2 (2001): 104-115.
   View at Publisher | View at Google Scholar
7. Rothman, Alan L. “Dengue: defining protective versus pathologic immunity.” The Journal of clinical investigation 113, no. 7 (2004): 946-951.
   View at Publisher | View at Google Scholar
8. Rothman, Alan L., and Francis A. Ennis. “Immunopathogenesis of dengue hemorrhagic fever.” Virology 257, no. 1 (1999): 1-6.
   View at Publisher | View at Google Scholar
9. Halstead, S. B., and Ph Simasthien. “Observations related to the pathogenesis of dengue hemorrhagic fever. II. Antigenic and biologic properties of dengue viruses and their association with disease response in the host.” The Yale journal of biology and medicine 42, no. 5 (1970): 276.
   View at Publisher | View at Google Scholar
10. Halstead, Scott B., Suchitra Nimmannitya, and S. N. Cohen. “Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered.” The Yale journal of biology and medicine 42, no. 5 (1970): 311.
    View at Publisher | View at Google Scholar
11. Halstead, S. B. “Global epidemiology of dengue hemorrhagic fever.” (1990): 636-641.
    View at Publisher | View at Google Scholar
12. Kliks, Srisakul C., Suchitra Nimmanitya, Ananda Nisalak, and Donald S. Burke. “Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants.” The American journal of tropical medicine and hygiene 38, no. 2 (1988): 411-419.
    View at Publisher | View at Google Scholar
13. Kliks, Srisakul C., Ananda Nisalak, Walter E. Brandt, Larry Wahl, and Donald S. Burke. “Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever.” The American journal of tropical medicine and hygiene 40, no. 4 (1989): 444-451.
    View at Publisher | View at Google Scholar
14. Libraty, Daniel H., Timothy P. Endy, Huo-Shu H. Houng, Sharone Green, Siripen Kalayanarooj, Saroj Suntayakorn, Wanya Chansiriwongs et al. “Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections.” The Journal of infectious diseases 185, no. 9 (2002): 1213-1221.
    View at Publisher | View at Google Scholar
15. Vaughn, David W., Sharone Green, Siripen Kalayanarooj, Bruce L. Innis, Suchitra Nimmannitya, Saroj Suntayakorn, Timothy P. Endy et al. “Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.” The Journal of infectious diseases 181, no. 1 (2000): 2-9.
    View at Publisher | View at Google Scholar
16. K Shahid, Sukhbir. “Recent patents in dengue disease management.” Pharmaceutical Patent Analyst 9, no. 6 (2020): 173- 185.
    View at Publisher | View at Google Scholar
17. Cologna, Raymond, and Rebeca Rico-Hesse. “American genotype structures decrease dengue virus output from human monocytes and dendritic cells.” Journal of virology 77, no. 7 (2003): 3929-3938.
    View at Publisher | View at Google Scholar
18. Pryor, MELINDA J., Jillian M. Carr, Helen Hocking, Andrew D. Davidson, Peng Li, and Peter J. Wright. “Replication of dengue virus type 2 in human monocyte-derived macrophages: comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein.” The American journal of tropical medicine and hygiene 65, no. 5 (2001): 427- 434.
    View at Publisher | View at Google Scholar
19. Watts, Douglas M., Kevin R. Porter, Pavithat Putvatana, Bruno Vasquez, Carlos Calampa, Curtis G. Hayes, and Scott B. Halstead. “Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever.” The Lancet 354, no. 9188 (1999): 1431-1434.
    View at Publisher | View at Google Scholar
20. Messer, William B., U. Tissa Vitarana, Kamalanayani Sivananthan, Jayanthi Elvtigala, L. D. Preethimala, R. Ramesh, Nalini Withana, Duane J. Gubler, and Aravinda M. De Silva. “Epidemiology of dengue in Sri Lanka before and after the emergence of epidemic dengue hemorrhagic fever.” The American journal of tropical medicine and hygiene 66, no. 6 (2002): 765-773.
    View at Publisher | View at Google Scholar
21. Green, Sharone, David W. Vaughn, Siripen Kalayanarooj, Suchitra Nimmannitya, Saroj Suntayakorn, Ananda Nisalak, Robert Lew et al. “Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity.” The Journal of infectious diseases 179, no. 4 (1999): 755-762.
    View at Publisher | View at Google Scholar
22. Hober, Didier, Lucien Poli, Bertrand Roblin, Philippe Gestas, Eliane Chungue, Gerard Granic, Patrick Imbert et al. “Serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) in dengue-infected patients.” The American journal of tropical medicine and hygiene 48, no. 3 (1993): 324-331.
    View at Publisher | View at Google Scholar
23. Hober, Didier, Trong Lan Nguyen, Lu Shen, Do Quang Ha, Vu Thi Que Huong, Samira Benyoucef, Thanh Hung Nguyen et al. “Tumor necrosis factor alpha levels in plasma and whole-blood culture in dengue-infected patients: Relationship between virus detection and pre-existing specific antibodies.” Journal of Medical Virology 54, no. 3 (1998): 210-218.
    View at Publisher | View at Google Scholar
24. Hober, Didier, Anne-Sophie Delannoy, Samira Benyoucef, Donat DE Groote, and Pierre Wattré. “High levels of sTNFR p75 and TNFα in dengue-infected patients.” Microbiology and immunology 40, no. 8 (1996): 569-573.
    View at Publisher | View at Google Scholar
25. Bethell, Delia B., Karin Flobbe, Cao Xuan, Thanh Phuong, Nicholas PJ Day, Pham Tung Phuong, Wim A. Buurman, M. J. Cardosa, Nicholas J. White, and Dominic Kwiatkowski. “Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever.” The Journal of infectious diseases 177, no. 3 (1998): 778-782.
    View at Publisher | View at Google Scholar
26. Guzman, Maria G., Duane J. Gubler, Alienys Izquierdo, Eric Martinez, and Scott B. Halstead. “Dengue infection.” Nature reviews Disease primers 2, no. 1 (2016): 1-25.
    View at Publisher | View at Google Scholar
27. Gibbons, Robert V., and David W. Vaughn. “Dengue: an escalating problem.” Bmj 324, no. 7353 (2002): 1563-1566.
    View at Publisher | View at Google Scholar
28. Putnak, J. Robert, Beth-Ann Coller, Gerald Voss, David W. Vaughn, David Clements, Iain Peters, Gary Bignami et al. “An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.” Vaccine 23, no. 35 (2005): 4442-4452.
    View at Publisher | View at Google Scholar
29. Maves, Ryan C., Roger M. Castillo Oré, Kevin R. Porter, and Tadeusz J. Kochel. “Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys.” Vaccine 29, no. 15 (2011): 2691- 2696.
    View at Publisher | View at Google Scholar
30. Dengue, W. H. O. I. “Guidelines for diagnosis, Treatment. Prevention and Control.” (No Title) (2009).
    View at Publisher | View at Google Scholar
31. Higa, Yukiko. “Dengue vectors and their spatial distribution.” Tropical medicine and health 39, no. 4SUPPLEMENT (2011): S17-S27.
    View at Publisher | View at Google Scholar
32. Bhatt, Samir, Peter W. Gething, Oliver J. Brady, Jane P. Messina, Andrew W. Farlow, Catherine L. Moyes, John M. Drake et al. “The global distribution and burden of dengue.” Nature 496, no. 7446 (2013): 504-507.
    View at Publisher | View at Google Scholar
33. Sampath, Aruna, Ting Xu, Alex Chao, Dahai Luo, Julien Lescar, and Subhash G. Vasudevan. “Structure-based mutational analysis of the NS3 helicase from dengue virus.” Journal of virology 80, no. 13 (2006): 6686-6690.
    View at Publisher | View at Google Scholar
34. Niyomrattanakit, Pornwaratt, Siti Nurdiana Abas, Chin Chin Lim, David Beer, Pei-Yong Shi, and Yen-Liang Chen. “A Fluorescence- Based Alkaline Phosphatase–Coupled Polymerase Assay for Identification of Inhibitors of Dengue Virus RNA-Dependent RNA Polymerase.” Journal of biomolecular screening 16, no. 2 (2011): 201-210.
    View at Publisher | View at Google Scholar
35. Rothan, Hussin A., Ammar Y. Abdulrahman, Pottayil G. Sasikumer, Shatrah Othman, Noorsaadah Abd Rahman, and Rohana Yusof. “Protegrin-1 Inhibits Dengue NS2B-NS3 Serine Protease and Viral Replication in MK2 Cells.” BioMed Research International 2012, no. 1 (2012): 251482.
    View at Publisher | View at Google Scholar
36. Byrd, Chelsea M., Douglas W. Grosenbach, Aklile Berhanu, Dongcheng Dai, Kevin F. Jones, Kara B. Cardwell, Christine Schneider et al. “Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase.” Antimicrobial agents and chemotherapy 57, no. 4 (2013): 1902-1912.
    View at Publisher | View at Google Scholar
37. Gong, Edwin Yunhao, Hannah Kenens, Tania Ivens, Koen Dockx, Katrien Vermeiren, Geneviève Vandercruyssen, Benoit Devogelaere, Pedro Lory, and Guenter Kraus. “Expression and purification of dengue virus NS5 polymerase and development of a high-throughput enzymatic assay for screening inhibitors of dengue polymerase.” Antiviral methods and protocols (2013): 237-247.
    View at Publisher | View at Google Scholar
38. Lai, Huiguo, Tadahisa Teramoto, and Radhakrishnan Padmanabhan. “Construction of dengue virus protease expression plasmid and in vitro protease assay for screening antiviral inhibitors.” Dengue: Methods and Protocols (2014): 345-360.
    View at Publisher | View at Google Scholar
39. Zellweger, Raphaël M., and Sujan Shresta. “Mouse models to study dengue virus immunology and pathogenesis.” Frontiers in immunology 5 (2014): 151.
    View at Publisher | View at Google Scholar
40. Züst, Roland, Ying-Xiu Toh, Iris Valdés, Daniela Cerny, Julia Heinrich, Lisset Hermida, Ernesto Marcos et al. “Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines.” Journal of virology 88, no. 13 (2014): 7276- 7285.
    View at Publisher | View at Google Scholar
41. Milligan, Gregg N., Vanessa V. Sarathy, Ernesto Infante, Li Li, Gerald A. Campbell, P. Robert Beatty, Eva Harris, Alan DT Barrett, and Nigel Bourne. “A dengue virus type 4 model of disseminated lethal infection in AG129 mice.” PloS one 10, no. 5 (2015): e0125476.
    View at Publisher | View at Google Scholar
42. Mutheneni, Srinivasa Rao, Andrew P. Morse, Cyril Caminade, and Suryanaryana Murty Upadhyayula. “Dengue burden in India: recent trends and importance of climatic parameters.” Emerging microbes & infections 6, no. 1 (2017): 1-10.
    View at Publisher | View at Google Scholar
43. Pinto, Amelia K., James D. Brien, Chia-Ying Kao Lam, Syd Johnson, Cindy Chiang, John Hiscott, Vanessa V. Sarathy, Alan D. Barrett, Sujan Shresta, and Michael S. Diamond. “Defining new therapeutics using a more immunocompetent mouse model of antibody-enhanced dengue virus infection.” MBio 6, no. 5 (2015): 10-1128.
    View at Publisher | View at Google Scholar
44. Sarathy, Vanessa V., Gregg N. Milligan, Nigel Bourne, and Alan DT Barrett. “Mouse models of dengue virus infection for vaccine testing.” Vaccine 33, no. 50 (2015): 7051-7060.
    View at Publisher | View at Google Scholar
45. Pierson, Theodore C., and Michael S. Diamond. “Vaccine development as a means to control dengue virus pathogenesis: do we know enough?.” Annual Review of Virology 1, no. 1 (2014): 375-398.
    View at Publisher | View at Google Scholar
46. Chan, Kuan Rong, Summer Li-Xin Zhang, Hwee Cheng Tan, Ying Kai Chan, Angelia Chow, Angeline Pei Chiew Lim, Subhash G. Vasudevan, Brendon J. Hanson, and Eng Eong Ooi. “Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection.” Proceedings of the National Academy of Sciences 108, no. 30 (2011): 12479- 12484.
    View at Publisher | View at Google Scholar
47. Guzman, Maria G., Mayling Alvarez, and Scott B. Halstead. “Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection.” Archives of virology 158 (2013): 1445-1459.
    View at Publisher | View at Google Scholar
48. Thomas, Laurent, Olivier Verlaeten, André Cabié, Stéphane Kaidomar, Victor Moravie, Jenny Martial, Fatiha Najioullah et al. “Influence of the dengue serotype, previous dengue infection, and plasma viral load on clinical presentation and outcome during a dengue-2 and dengue-4 co-epidemic.” American Journal of Tropical Medicine and Hygiene 78, no. 6 (2008): 990-998.
    View at Publisher | View at Google Scholar
49. Low, Jenny GH, Eng-Eong Ooi, Thomas Tolfvenstam, Yee-Sin Leo, Martin L. Hibberd, Lee-Ching Ng, Yee-Ling Lai et al. “Early Dengue infection and outcome study (EDEN)-study design and preliminary findings.” Annals-Academy of Medicine Singapore 35, no. 11 (2006): 783.
    View at Publisher | View at Google Scholar
50. Libraty, Daniel H., Timothy P. Endy, Huo-Shu H. Houng, Sharone Green, Siripen Kalayanarooj, Saroj Suntayakorn, Wanya Chansiriwongs et al. “Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections.” The Journal of infectious diseases 185, no. 9 (2002): 1213-1221.
    View at Publisher | View at Google Scholar
51. Malavige, Gathsaurie Neelika, Li-Chieh Huang, Maryam Salimi, Laksiri Gomes, S. D. Jayaratne, and Graham S. Ogg. “Cellular and cytokine correlates of severe dengue infection.” PLOS one 7, no. 11 (2012): e50387.
    View at Publisher | View at Google Scholar
52. Rathakrishnan, Anusyah, Seok Mui Wang, Yongli Hu, Asif M. Khan, Sasheela Ponnampalavanar, Lucy Chai See Lum, Rishya Manikam, and Shamala Devi Sekaran. “Cytokine expression profile of dengue patients at different phases of illness.” PloS one 7, no. 12 (2012): e52215.
    View at Publisher | View at Google Scholar
53. Fink, Joshua, Feng Gu, Ling Ling, Thomas Tolfvenstam, Farzad Olfat, Keh Chuang Chin, Pauline Aw et al. “Host gene expression profiling of dengue virus infection in cell lines and patients.” PLoS neglected tropical diseases 1, no. 2 (2007): e86.
    View at Publisher | View at Google Scholar
54. Tolfvenstam, Thomas, Anna Lindblom, Mark J. Schreiber, Ling Ling, Angelia Chow, Eng Eong Ooi, and Martin L. Hibberd. “Characterization of early host responses in adults with dengue disease.” BMC infectious diseases 11 (2011): 1-7.
    View at Publisher | View at Google Scholar
55. Sun, Peifang, Josefina García, Guillermo Comach, Maryanne T. Vahey, Zhining Wang, Brett M. Forshey, Amy C. Morrison et al. “Sequential waves of gene expression in patients with clinically defined dengue illnesses reveal subtle disease phases and predict disease severity.” PLoS neglected tropical diseases 7, no. 7 (2013): e2298.
    View at Publisher | View at Google Scholar
56. Devignot, Stephanie, Cédric Sapet, Veasna Duong, Aurélie Bergon, Pascal Rihet, Sivuth Ong, Patrich T. Lorn et al. “Genome- wide expression profiling deciphers host responses altered during dengue shock syndrome and reveals the role of innate immunity in severe dengue.” PloS one 5, no. 7 (2010): e11671.
    View at Publisher | View at Google Scholar
57. Ubol, Sukathida, Promsin Masrinoul, Jeerayut Chaijaruwanich, Siripen Kalayanarooj, Takol Charoensirisuthikul, and Jitra Kasisith. “Differences in global gene expression in peripheral blood mononuclear cells indicate a significant role of the innate responses in progression of dengue fever but not dengue hemorrhagic fever.” The Journal of infectious diseases 197, no. 10 (2008): 1459-1467.
    View at Publisher | View at Google Scholar
58. Yacoub, Sophie, Heiman Wertheim, Cameron P. Simmons, Gavin Screaton, and Bridget Wills. “Cardiovascular manifestations of the emerging dengue pandemic.” Nature reviews cardiology 11, no. 6 (2014): 335-345.
    View at Publisher | View at Google Scholar
59. Wang, Wei-Kung, Day-Yu Chao, Chuan-Liang Kao, Han-Chung Wu, Yung-Ching Liu, Chien-Ming Li, Shih-Chung Lin, Shih-Ting Ho, Jyh-Hsiung Huang, and Chwan-Chuen King. “High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis.” Virology 305, no. 2 (2003): 330-338.
    View at Publisher | View at Google Scholar
60. Guilarde, Adriana O., Marilia D. Turchi, Joao Bosco Siqueira Jr, Valeria C. R. Feres, Benigno Rocha, Jose E. Levi, Vanda AU F. Souza, Lucy Santos Vilas Boas, Claudio S. Pannuti, and Celina M. T. Martelli. “Dengue and dengue hemorrhagic fever among adults: clinical outcomes related to viremia, serotypes, and antibody response.” The Journal of infectious diseases 197, no. 6 (2008): 817-824.
    View at Publisher | View at Google Scholar
61. Wang, Wei-Kung, Hui-Ling Chen, Chao-Fu Yang, Szu-Chia Hsieh, Chung-Chou Juan, Shu-Mei Chang, Cheng-Ching Yu, Li-Hui Lin, Jyh-Hsiung Huang, and Chwan-Chuen King. “Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever.” Clinical Infectious Diseases 43, no. 8 (2006): 1023-1030.
    View at Publisher | View at Google Scholar
62. Vaughn, David W., Sharone Green, Siripen Kalayanarooj, Bruce L. Innis, Suchitra Nimmannitya, Saroj Suntayakorn, Timothy P. Endy et al. “Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.” The Journal of infectious diseases 181, no. 1 (2000): 2-9.
    View at Publisher | View at Google Scholar
63. Murgue, Bernadette, Claudine Roche, Eliane Chungue, and Xavier Deparis. “Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996–1997 dengue-2 outbreak in French Polynesia.” Journal of medical virology 60, no. 4 (2000): 432-438.
    View at Publisher | View at Google Scholar
64. Nhan, Ngo Thi, Cao Xuan Thanh Phuong, Rachel Kneen, Bridget Wills, Nguyen Van My, Nguyen Thi Que Phuong, Chu Van Thien et al. “Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour.” Clinical Infectious Diseases 32, no. 2 (2001): 204-213.
    View at Publisher | View at Google Scholar
65. Wagner, B. K., and Louis F. D’Amelio. “Pharmacologic and clinical considerations in selecting crystalloid, colloidal, and oxygen- carrying resuscitation fluids, Part 1.” Clinical pharmacy 12, no. 5 (1993): 335-346.
    View at Publisher | View at Google Scholar
66. Wills, Bridget A., Nguyen M. Dung, Ha T. Loan, Dong TH Tam, Tran TN Thuy, Le TT Minh, Tran V. Diet et al. “Comparison of three fluid solutions for resuscitation in dengue shock syndrome.” New England Journal of Medicine 353, no. 9 (2005): 877-889.
    View at Publisher | View at Google Scholar
67. Dung, N. M., N. P. J. Day, D. T. H. Tam, H. T. Loan, H. T. T. Chau, L. N. Minh, T. V. Diet et al. “Fluid replacement in dengue shock syndrome: a randomized, double-blind comparison of four intravenous-fluid regimens.” Clinical Infectious Diseases 29, no. 4 (1999): 787-794.
    View at Publisher | View at Google Scholar
68. Kalayanarooj, Siripen. “Choice of colloidal solutions in dengue hemorrhagic fever patients.” J Med Assoc Thai 91, no. Suppl 3 (2008): S97-103.
    View at Publisher | View at Google Scholar
69. Dellinger, R. Phillip, Mitchell M. Levy, Andrew Rhodes, Djillali Annane, Herwig Gerlach, Steven M. Opal, Jonathan E. Sevransky et al. “Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012.” Critical care medicine 41, no. 2 (2013): 580-637.
    View at Publisher | View at Google Scholar
70. Lum, Lucy Chai See, Adrian Yu Teik Goh, Patrick Wai Keong Chan, Abdel-Latif Mohd El-Amin, and Sai Kit Lam. “Risk factors for hemorrhage in severe dengue infections.” The Journal of pediatrics 140, no. 5 (2002): 629-631.
    View at Publisher | View at Google Scholar
71. Leo, Yee-Sin, Tun L. Thein, Dale A. Fisher, Jenny G. Low, Helen M. Oh, Rajmohan L. Narayanan, Victor C. Gan, Vernon J. Lee, and David C. Lye. “Confirmed adult dengue deaths in Singapore: 5-year multi-center retrospective study.” BMC infectious diseases 11 (2011): 1-7.
    View at Publisher | View at Google Scholar
72. Lye, David C., Vernon J. Lee, Yan Sun, and Yee Sin Leo. “Lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in adults with acute uncomplicated dengue infection.” Clinical infectious diseases 48, no. 9 (2009): 1262-1265.
    View at Publisher | View at Google Scholar
73. Krishnamurti, C. H. I. T. R. A., S. I. R. I. P. E. N. Kalayanarooj, MARY A. Cutting, RAQUEL A. Peat, STEPHEN W. Rothwell, THOMAS J. Reid, S. H. A. R. O. N. E. Green et al. “Mechanisms of hemorrhage in dengue without circulatory collapse.” The American journal of tropical medicine and hygiene 65, no. 6 (2001): 840-847.
    View at Publisher | View at Google Scholar
74. Sellahewa, K. H., N. Samaraweera, K. P. G. D. Thusita, and J. L. I. N. Fernando. “Is fresh frozen plasma effective for thrombocytopenia in adults with dengue fever? A prospective randomised double blind controlled study.” Ceylon Medical Journal 53, no. 2 (2008).
    View at Publisher | View at Google Scholar
75. Assir, Muhammad Zaman Khan, Umair Kamran, Hafiz Ijaz Ahmad, Sadia Bashir, Hassan Mansoor, Saad Bin Anees, and Javed Akram. “Effectiveness of platelet transfusion in dengue fever: a randomized controlled trial.” Transfusion Medicine and Hemotherapy 40, no. 5 (2013): 362-368.
    View at Publisher | View at Google Scholar
76. Hahn, Bevra H., Maureen A. Mcmahon, Alan Wilkinson, W. Dean Wallace, David I. Daikh, John D. Fitzgerald, George A. Karpouzas et al. “American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.” Arthritis care & research 64, no. 6 (2012): 797-808.
    View at Publisher | View at Google Scholar
77. Pongpanich, B., P. Bhanchet, P. Phanichyakarn, and A. Valyasevi. “Studies on dengue hemorrhagic fever. Clinical study: an evaluation of steroids as a treatment.” (1973): 6-14.
    View at Publisher | View at Google Scholar
78. Min, Myo, M. Aye, T. N. Shwe, and T. Swe. “Hydrocortisone in the management of dengue shock syndrome.” The Southeast Asian journal of tropical medicine and public health 6, no. 4 (1975): 573-579.
    View at Publisher | View at Google Scholar
79. Sumarmo, Dummy, Widodo Talogo, Arnis Asrin, Bachrudin Isnuhandojo, and Achmad Sahudi. “Failure of hydrocortisone to affect outcome in dengue shock syndrome.” Pediatrics 69, no. 1 (1982): 45-49.
    View at Publisher | View at Google Scholar
80. Tassniyom, Sompon, Sirijitt Vasanawathana, Aroon Chirawatkul, and Suntharee Rojanasuphot. “Failure of high-dose methylprednisolone in established dengue shock syndrome: a placebo-controlled, double-blind study.” Pediatrics 92, no. 1 (1993): 111-115.
    View at Publisher | View at Google Scholar
81. Kularatne, S. A. M., C. Walathara, S. I. Mahindawansa, S. Wijesinghe, M. M. K. Pathirage, P. V. R. Kumarasiri, and A. M. S. D. M. Dissanayake. “Efficacy of low dose dexamethasone in severe thrombocytopenia caused by dengue fever: a placebo controlled study.” Postgraduate medical journal 85, no. 1008 (2009): 525-529.
    View at Publisher | View at Google Scholar
82. Tam, Dong TH, Tran V. Ngoc, Nguyen TH Tien, Nguyen TT Kieu, Truong TT Thuy, Lai TC Thanh, Cao T. Tam et al. “Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial.” Clinical Infectious Diseases 55, no. 9 (2012): 1216-1224.
    View at Publisher | View at Google Scholar
83. Shashidhara, K. C., KA Sudharshan Murthy, H. Basavana Gowdappa, and Abhijith Bhograj. “Effect of high dose of steroid on plateletcount in acute stage of dengue fever with thrombocytopenia.” Journal of clinical and diagnostic research: JCDR 7, no. 7 (2013): 1397.
    View at Publisher | View at Google Scholar
84. Panpanich, Ratana, P. Sornchai, and Kittika Kanjanaratanakorn. “Corticosteroids for treating dengue shock syndrome.” Cochrane Database of Systematic Reviews 3 (2006).
    View at Publisher | View at Google Scholar
85. Samuelsson, Astrid, Terri L. Towers, and Jeffrey V. Ravetch. “Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.” Science 291, no. 5503 (2001): 484-486.
    View at Publisher | View at Google Scholar
86. Dimaano, Efren M., Mariko Saito, Shoko Honda, Edna A. Miranda, Maria TG Alonzo, Myra D. Valerio, Cynthia A. Mapua et al. “Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection.” American Journal of Tropical Medicine and Hygiene 77, no. 6 (2007): 1135-1138.
    View at Publisher | View at Google Scholar
87. St John, Ashley L., Abhay PS Rathore, Bhuvanakantham Raghavan, Mah-Lee Ng, and Soman N. Abraham. “Contributions of mast cells and vasoactive products, leukotrienes and chymase, to dengue virus-induced vascular leakage.” elife 2 (2013): e00481.
    View at Publisher | View at Google Scholar
88. St. John, Ashley L., Abhay PS Rathore, Han Yap, Mah-Lee Ng, Dean D. Metcalfe, Subhash G. Vasudevan, and Soman N. Abraham. “Immune surveillance by mast cells during dengue infection promotes natural killer (NK) and NKT-cell recruitment and viral clearance.” Proceedings of the National Academy of Sciences 108, no. 22 (2011): 9190-9195.
    View at Publisher | View at Google Scholar
89. Apte-Sengupta, Swapna, Devika Sirohi, and Richard J. Kuhn. “Coupling of replication and assembly in flaviviruses.” Current opinion in virology 9 (2014): 134-142.
    View at Publisher | View at Google Scholar
90. Tricou, Vianney, Nguyet Nguyen Minh, Toi Pham Van, Sue J. Lee, Jeremy Farrar, Bridget Wills, Hien Tinh Tran, and Cameron P. Simmons. “A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults.” PLoS neglected tropical diseases 4, no. 8 (2010): e785.
    View at Publisher | View at Google Scholar
91. Modis, Yorgo, Steven Ogata, David Clements, and Stephen C. Harrison. “Structure of the dengue virus envelope protein after membrane fusion.” Nature 427, no. 6972 (2004): 313-319.
    View at Publisher | View at Google Scholar
92. Savarino, Adrea, John R. Boelaert, Antonio Cassone, Giancario Majori, and Roberto Cauda. “Effects of chloroquine on viral infections: an old drug against today’s diseases.” The Lancet infectious diseases 3, no. 11 (2003): 722-727.
    View at Publisher | View at Google Scholar
93. Borges, Marcos Carvalho, Luiza Antunes Castro, and Benedito Antonio Lopes da Fonseca. “Chloroquine use improves dengue- related symptoms.” Memórias do Instituto Oswaldo Cruz 108, no. 5 (2013): 596-599.
    View at Publisher | View at Google Scholar
94. Courageot, Marie-Pierre, Marie-Pascale Frenkiel, Claudia Duarte Dos Santos, Vincent Deubel, and Philippe Desprès. “α-Glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum.” Journal of virology 74, no. 1 (2000): 564- 572.
    View at Publisher | View at Google Scholar
95. Rathore APS, Paradkar PN, Watanabe S et al.Antiviral research. Antiviral Res. 92(3), 453–460 (2011).
    View at Publisher | View at Google Scholar
96. Durantel, David. “Celgosivir, an αglucosidase I inhibitor for the potential treatment of hepatitis C virus infection.” Curr. Opin. Investig. Drugs 10, no. 8 (2009): 860-870.
    View at Publisher | View at Google Scholar
97. Low, Jenny G., Cynthia Sung, Limin Wijaya, Yuan Wei, Abhay PS Rathore, Satoru Watanabe, Boon Hian Tan et al. “Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial.” The Lancet infectious diseases 14, no. 8 (2014): 706-715.
    View at Publisher | View at Google Scholar
98. Martinez-Gutierrez, Marlen, Luis A. Correa-Londoño, Jaime E. Castellanos, Juan C. Gallego-Gómez, and Jorge E. Osorio. “Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2.” PloS one 9, no. 2 (2014): e87412.
    View at Publisher | View at Google Scholar
99. Rachoin, Jean-Sebastien, Elizabeth Cerceo, and R. Phillip Dellinger. “A new role for statins in sepsis.” Critical Care 17 (2013): 1-2.
    View at Publisher | View at Google Scholar
100. Whitehorn, James, Nguyen Van Vinh Chau, Nguyen Thanh Truong, Luong Thi Hue Tai, Nguyen Van Hao, Tran Tinh Hien, Marcel Wolbers et al. “Lovastatin for adult patients with dengue: protocol for a randomised controlled trial.” Trials 13 (2012): 1-6.
     View at Publisher | View at Google Scholar
101. Whitehorn, James, Sophie Yacoub, Katherine L. Anders, Louis R. Macareo, M. Cristina Cassetti, Vinh Chau Nguyen Van, Pei- Yong Shi, Bridget Wills, and Cameron P. Simmons. “Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions.” PLoS neglected tropical diseases 8, no. 8 (2014): e3025.
     View at Publisher | View at Google Scholar
102. Dengue Virus Net. “Aedes aegypti.” Dengue transmission by Aedes aegypti mosquito (2011). Department of Medical Entomology, University of Sydney and Westmead Hospital, Australia. Aedes aegypti (2010). Kuno, G. “Factors Influencing the Transmission of Dengue Viruses.” In Dengue and Dengue Hemorrhagic Fever, eds. D. J. Gubler & G. Kuno (Cambridge: CABI, 2001): 61–88.
     View at Publisher | View at Google Scholar
103. Rodhain, François, and Leon Rosen. “Mosquito vectors and dengue virus-vector relationships.” (1997): 45-60.
     View at Publisher | View at Google Scholar
104. World Health Organization. “Special programme for research and training in tropical diseases.” (1978).
     View at Publisher | View at Google Scholar
105. Bellah, Sm Faysal, Firoj Ahmed Firoj Ahmed, A. A. Rahman, I. Z. Shahid, and SM Moazzem Hossen. “Preliminary phytochemical, anti-bacterial, analgesic, anti-diarrhoeal and cytotoxic activity of methanolic extract of polyalthia suberosa leaves.” (2012): 1322-1326.
     View at Publisher | View at Google Scholar
106. Howlader, Md Sariful Islam, Muhammad Shahdaat Bin Sayeed, Maizbha Uddin Ahmed, Abdul Kader Mohiuddin, Zubair Khalid Labu, Sm Faysal Bellah, and Mohammad Safiqul Islam. “Characterization of chemical groups and study of antioxidant, antidiarrhoeal, antimicrobial and cytotoxic activities of ethanolic extract of Diospyros blancoi (Family: Ebenaceae) leaves.” J Pharm Res 5, no. 6 (2012): 3050-3052.
     View at Publisher | View at Google Scholar
107. Momin, Mohammad Abdul Motalib, Sm Faysal Bellah, Afrina Afrose, Kaniz Fatima Urmi, Kaiser Hamid, and Md Sohel Rana. “Phytochemical screening and cytotoxicity potential of ethanolic extracts of Senna siamea leaves.” Journal of Pharmaceutical Sciences and Research 4, no. 8 (2012): 1877.
     View at Publisher | View at Google Scholar
108. Momin, Mohammad Abdul Motalib, Sm Faysal Bellah, Mizanur Rahaman Khan, Md Iqubal Hossain Raju, Md Mustafizur Rahman, and Anjuman Ara Begum. “Phytopharmacological evaluation of ethanolic extract of Feronia limonia leaves.” America Journal of Scientific and Industrial Research Science 4, no. 5 (2013): 468-472.
     View at Publisher | View at Google Scholar
109. Momin, Mohammad Abdul Motalib, Sm Faysal Bellah, Sarder Mohammad Raussel Rahman, Ahmed Ayedur Rahman, Gazi Mohammad Monjur Murshid, and Talha Bin Emran. “Phytopharmacological evaluation of ethanol extract of Sida cordifolia L. roots.” Asian Pacific journal of tropical biomedicine 4, no. 1 (2014): 18-24.
     View at Publisher | View at Google Scholar
110. Bellah, Sm Faysal, Md Iqubal Hossain Raju, SM Saker Billah, Shaikh Emdadur Rahman, G. M. M. Murshid, and Md Mustafizur Rahman. “Evaluation of antibacterial and antidiarrhoeal activity of ethanolic extract of Feronia limonia Leaves.” The Pharma Innovation 3, no. 11, Part B (2015): 50.
     View at Publisher | View at Google Scholar
111. Bellah, SM Faysal, Md Nur Islam, Md Rezaul Karim, Md Masudur Rahaman, Mst Samima Nasrin, Md Atiar Rahman, and ASM Ali Reza. “Evaluation of cytotoxic, analgesic, antidiarrheal and phytochemical properties of Hygrophila spinosa (T. Anders) whole plant.” Journal of basic and clinical physiology and pharmacology 28, no. 2 (2017): 185-190.
     View at Publisher | View at Google Scholar